iShares Biotechnology ETF (NASDAQ:IBB) Shares Sold by Kovack Advisors Inc.

Kovack Advisors Inc. lowered its holdings in iShares Biotechnology ETF (NASDAQ:IBB) by 6.2% in the third quarter, according to its most recent Form 13F filing with the SEC. The fund owned 1,956 shares of the financial services provider’s stock after selling 130 shares during the period. Kovack Advisors Inc.’s holdings in iShares Biotechnology ETF were worth $285,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently bought and sold shares of the business. Oppenheimer & Co. Inc. grew its holdings in iShares Biotechnology ETF by 0.7% during the 3rd quarter. Oppenheimer & Co. Inc. now owns 35,663 shares of the financial services provider’s stock worth $5,193,000 after acquiring an additional 237 shares in the last quarter. Aptus Capital Advisors LLC lifted its position in shares of iShares Biotechnology ETF by 36.5% during the third quarter. Aptus Capital Advisors LLC now owns 426 shares of the financial services provider’s stock worth $62,000 after purchasing an additional 114 shares during the last quarter. Peregrine Asset Advisers Inc. grew its stake in iShares Biotechnology ETF by 6.8% in the third quarter. Peregrine Asset Advisers Inc. now owns 3,467 shares of the financial services provider’s stock worth $505,000 after purchasing an additional 222 shares in the last quarter. Ashton Thomas Securities LLC bought a new stake in iShares Biotechnology ETF in the third quarter valued at about $36,000. Finally, Tyler Stone Wealth Management raised its stake in iShares Biotechnology ETF by 128.0% during the third quarter. Tyler Stone Wealth Management now owns 5,747 shares of the financial services provider’s stock valued at $837,000 after buying an additional 3,226 shares in the last quarter. Institutional investors and hedge funds own 62.45% of the company’s stock.

iShares Biotechnology ETF Stock Down 4.8 %

NASDAQ:IBB opened at $133.38 on Friday. The business’s 50 day moving average is $144.49 and its two-hundred day moving average is $141.59. iShares Biotechnology ETF has a 52 week low of $116.70 and a 52 week high of $150.57.

iShares Biotechnology ETF Dividend Announcement

The company also recently disclosed a dividend, which was paid on Monday, September 30th. Investors of record on Wednesday, September 25th were paid a dividend of $0.2005 per share. The ex-dividend date of this dividend was Wednesday, September 25th.

iShares Biotechnology ETF Profile

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.